What You Should Know:
– Medtronic announced an expanded AI partnership with Cosmo Pharmaceuticals NV, a pharmaceutical company, to further advance AI-powered solutions in the medical field.
– This strategic alliance builds upon the success of the GI Genius™ intelligent endoscopy module, aiming to revolutionize endoscopy through AI and improve patient outcomes globally.
Partnership Benefits
Building upon the success of the GI Genius™ intelligent endoscopy module, the partnership will focus on:
– AI Access™ platform: This innovative platform will serve as a hub for hosting multiple third-party AI applications, accelerating innovation and streamlining the development process across various medical AI applications.
– GI Genius™ module: This FDA-cleared AI system for polyp detection has already demonstrated significant impact, increasing adenoma detection rates by 14% in gastroenterologists performing colonoscopies.
– Exclusive global partnership: This reinforces Medtronic’s position in AI-integrated healthcare solutions and grants them exclusive commercial rights for the GI Genius platform.
Financial terms
Medtronic will pay Cosmo Pharmaceuticals an upfront payment of $100M, double-digit royalty on net sales, and potential milestone payments of $100M by the end of 2024. Cosmo Pharmaceuticals remains the exclusive manufacturer of the platform.
“This expanded agreement is a testament to our mutual commitment to rapidly improving the healthcare landscape. Our continued partnership with Medtronic is pivotal in further enabling the GI Genius platform to offer enhanced AI solutions and improved clinical outcomes to patients globally,” said Alessandro Della Chà, Cosmo Pharmaceuticals CEO.
